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Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) probably plays an important role in the
development of acute coronary syndrome (ACS); elevated levels of Lp-PLA2 are associated with a poorer prognosis
in patients with ischemic heart disease. Alterations of Lp-PLA2 levels during ACS and its relationship to standard
biomarkers are, however, unclear.
Findings: Fifty-one consecutive ACS patients were enrolled in the study. All were managed with early invasive strategy
and according to the current guidelines for pharmacotherapy; intensive statin therapy was started in all patients at
admission. Serum levels of Lp-PLA2, LDL-cholesterol (LDL), troponin l (Tnl), and C-reactive protein (CRP) were assessed
at admission (D0), on the first morning (D1), and on the second morning of hospitalization (D2). Mean serum levels of
Lp-PLA2 (ng/mL) decreased from 264.6±19.1 at D0, to 193.2±14.4 at D1 (P < 0.001 vs. D0) and 189.8±22.6 at D2
(P = 0.002 vs. D0; P = not significant vs. D1). Alterations in Lp-PLA2 levels significantly correlated with changes in LDL
(r = 0.43; P = 0.008). On the other hand, no relationship between Lp-PLA2 and Tnl or CRP was found.
Conclusions: Initially, serum levels of Lp-PLA2 were significantly elevated in ACS patients, but decreased within the first
24 hours after admission and subsequently remained stable. Lp-PLA2 levels correlated with LDL levels but not with Tnl
or CRP levels. Our results demonstrated dynamic alterations in Lp-PLA2 levels during the early stages of ACS and,
therefore, indirectly support the hypothesis of an active role for Lp-PLA2 in the pathogenesis of ACS.
Keywords: Acute coronary syndrome, C-reactive protein, Lipoprotein-associated phospholipase A2, Low-density
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Cardiovascular diseases are the leading cause of death and
disability in developed countries; atherosclerosis and
thrombosis are the pathogenic mechanisms responsible
for the majority of cardiovascular events. Several factors
have been hypothesized to participate in the development
of atherosclerosis; however, the precise mechanisms of
atherosclerotic plaque formation, its vulnerability, and
possible disruption remain unclear. Recently, lipoprotein-
associated phospholipase A2 (Lp-PLA2) was introduced
not only as a risk factor markedly associated with a higher
incidence of cardiovascular events, but also as a potentially* Correspondence: ostadal.petr@gmail.com
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reproduction in any medium, provided the orimportant pathogenic factor participating in the progres-
sion of atherosclerosis [1].
Lp-PLA2 is an enzyme produced by inflammatory cells
such as macrophages, foam cells and mast cells, as well
as T-lymphocytes in atherosclerotic plaques and by liver
cells [2]. Lp-PLA2 is responsible for the hydrolysis of
oxidized phospholipids, and leads to the production of
highly pro-inflammatory products (lysophosphatidylcho-
line and oxidized non-esterified fatty acids) [2]. In the
blood, Lp-PLA2 is predominantly associated with low-
density lipoprotein (LDL) [2]. Lp-PLA2 has been found in
both stable and vulnerable atherosclerotic plaques. How-
ever, a significantly higher concentration of Lp-PLA2 has
been reported in vulnerable and ruptured plaques. In
these unstable plaques, Lp-PLA2 is localized not only to
the necrotic core, but also in the subendothelial space ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of the study group (n=51)
N %










CAD, Coronary artery disease; ACS, Acute coronary syndrome; STE, ST-elevation
on electrocardiogram; NSTE, Non-ST-elevation on electrocardiogram.
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http://www.lipidworld.com/content/11/1/153regions within the thin fibrous cap or at the site of plaque
rupture [3,4].
Numerous epidemiological studies have demonstrated
the correlation between elevated Lp-PLA2 levels and
increased risk for both primary and secondary cardiovas-
cular events [5,6]. Moreover, although Lp-PLA2 has
been shown to be an independent risk factor, enzyme
activity and mass positively correlated with LDL-Figure 1 Alterations in serum levels of Lp-PLA2, LDL, CRP, and Tnl. Bl
hospitalization (D1), and second morning of hospitalization (D2). The Wilco
Lp-PLA2, Lipoprotein-associated phospholipase A2; LDL, Low-density lipoprcholesterol and triglyceride levels, and was inversely asso-
ciated with high-density lipoprotein (HDL)-cholesterol
[6]. Several studies have focused on patients with acute
coronary syndrome (ACS), usually with a single Lp-PLA2
measurement at enrollment [7-10]. Possible early altera-
tions of Lp-PLA2 levels during the development of ACS
and their relationship with standard biomarkers have not,
however, been extensively studied.
The study protocol was approved by the institutional
ethics review committee, and written informed consent
was obtained from all participating subjects. Fifty-one
consecutive patients admitted to the Coronary Care Unit
for ACS at the Na Homolce Hospital (Prague, Czech
Republic) between January and April 2010 were enrolled
in the present study. Eligible patients with ST-elevation
ACS experienced chest pain at rest less than 12 hours
before admission and ≥ 1 mm ST-segment elevation in
two or more contiguous leads, or new left bundle branch
block on electrocardiogram. Eligible patients with non-
ST elevation ACS experienced chest pain at rest during
the previous 12 hours and ≥ 1 mm ST segment depres-
sion or negative T waves in two or more contiguous
leads. All participants were managed with early inva-
sive strategy (ie, they underwent urgent coronaryood samples were taken at admission (D0), first morning of
xon matched-pairs signed-rank test was used for statistical analysis.
otein cholesterol; CRP, C-reactive protein; Tnl, Troponin I.
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necessary). All patients were treated with aspirin and he-
parin according to the current guidelines for pharmaco-
therapy, and all patients received clopidogrel immediately.
Beta-blockers and angiotensin-converting enzyme inhibi-
tors were administered to patients according to their cli-
nical condition after stabilization; intensive statin therapy
was started in all patients at admission. Blood samples for
the measurement of Lp-PLA2, LDL, troponin I (Tnl), and
C-reactive protein (CRP) levels were drawn at admission
(D0), the first morning (D1), and the second morning ofFigure 2 Correlation of Lp-PLA2 and LDL. Blood samples were
taken at admission (D0), first morning of hospitalization (D1), and
second morning of hospitalization (D2). Data were analyzed using
the Spearman correlation test. Lp-PLA2, Lipoprotein-associated
phospholipase A2; LDL, Low-density lipoprotein cholesterol; Δ (D0-D1),
Difference in levels from D0 to D1.hospitalization (D2). Mass measurements of Lp-PLA2
were performed using a commercially available sandwich
enzyme immunoassay that is based on two specific mono-
clonal antibodies (PLAC Test, diaDexus, USA). LDL levels
were measured by photometric enzyme assay using the
UNICEL DxC 800f Automatic Analyzer System (Beckman
Coulter, USA). Tnl was assessed by chemiluminescent im-
munoassay using the DxI 600f Automatic Analyzer Sys-
tem (Beckman Coulter, USA). CRP was measured using
an immunoturbidimetric assay (K-Assay, Kamiya Biomed-
ical Company, USA). Data are expressed as mean ± stand-
ard error. Alterations in Lp-PLA2, LDL, CRP, and Tnl
levels were analyzed using the Wilcoxon matched-pairs
signed-rank test. Correlations of Lp-PLA2 with other bio-
markers were evaluated using the Spearman correlation,
with P < 0.05 considered to be statistically significant.
Baseline demographic data, cardiovascular risk fac-
tors, and infarction type are shown in Table 1. The
mean age of the study population was 62.7 years, the
majority of which was male (69%). ST-elevation ACS
was experienced by 65% of enrolled subjects (Table 1).
The mean serum level of Lp-PLA2 (ng/mL) decreased
significantly from 264.6 ± 19.1 at D0, to 193.2 ± 14.4
at D1 (P < 0.001 vs. D0) and remain unchanged at
D2 (189.8 ± 22.6; P = 0.002 vs. D0; P = 0.35 vs. D1)
(Figure 1A). Alterations in LDL, CRP, and Tnl levels
are shown in Figure 1B to D. Significant correlation
was found between the levels of Lp-PLA2 and LDL
at D0 (r = 0.34; 95% CI 0.04-0.58; P = 0.021) and D1
(r = 0.39; 95% CI 0.09-0.62; P = 0.01) (Figure 2A to
B). Alterations of Lp-PLA2 levels between D0 and D1
positively correlated with the corresponding changes
in LDL levels (r = 0.43; 95% CI 0.12-0.67; P = 0.008)
(Figure 2C). No correlation was found between Lp-
PLA2 and CRP or Tnl levels (Table 2).
The major findings of the present study were the rapid
changes in Lp-PLA2 levels in the early phases of ACS:
elevated levels of Lp-PLA2 decreased during the first 24
hours and subsequently remained stable. Furthermore,
we found a significant correlation between Lp-PLA2 andTable 2 Correlation of Lp-PLA2 with other biomarkers
Lp-PLA2
D0 D1 D2 D0-D1
LDL r 0.34 0.39 0.13 0.43
P 0.02 0.01 0.67 <0.01
CRP r −0.08 0.03 0.01 0.06
P 0.57 0.81 0.82 0.70
Tnl r −0.05 0.10 0.08 −0.09
P 0.70 0.49 0.66 0.57
Analysis was performed using Spearman correlation. CRP, C-reactive
protein; D0 At admission; D1 First morning of hospitalization; D2 Second
morning of hospitalization; LDL, Low-density lipoprotein cholesterol;
Lp-PLA2, Lipoprotein-associated phospholipase A2; Tnl, Troponin 1.
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lationship between Lp-PLA2 levels and other biomarkers
(CRP and Tnl).
To date, several studies have focused on the assess-
ment of Lp-PLA2 in patients with ACS [7-10]; however,
none of them used repetitive measurements as in our
study. In partial discordance with our results are obser-
vations reported by Oldgren et al. [10], who reported
that the time delay from symptom onset to blood sam-
pling did not influence Lp-PLA2 levels. We enrolled all
participants within 12 hours of symptom onset. Further-
more, the rapid decrease in Lp-PLA2 levels observed in
our study were influenced not only by the pathogenic
mechanisms participating in the development of ACS,
but also by the intensive statin therapy routinely started
in our patients at admission. It has been shown that
long-term intensive statin therapy may decrease not only
LDL levels (by 40 to 60%), but also Lp-PLA2 levels (by
more than 20%) [8]. Moreover, it has been reported that
the acute effect of statins on LDL is detectable in ACS
patients during the first 24 hours after therapy initiation
[11,12]. In the present study, both LDL and Lp-PLA2
levels were significantly reduced in the first 24 hours. In
contrast to studies of long-term, intensive statin therapy
[8], we observed a less marked reduction in LDL levels
than in Lp-PLA2 levels.
Our data regarding the correlation of Lp-PLA2 and
LDL are in good agreement with other reports. A re-
cently published meta-analysis of clinical trials investi-
gating Lp-PLA2 [6] showed a strong correlation between
Lp-PLA2 and LDL, in addition to correlation with other
lipid parameters. Similar to our results, the authors of
the meta-analysis [6] did not find any correlation be-
tween Lp-PLA2 and CRP. On the other hand, a weak,
yet statistically significant correlation between Lp-PLA2
and CRP was observed in some other cohorts of ACS
patients [10].
The present study has several limitations, most of
which were due to the limited size of the study popula-
tion. It can also be argued that the inclusion of both
types of ACS (ST elevation and non-ST elevation) may
have increased the heterogeneity of the study group. We
included both types of ACS patients based on the same
(or at least very similar) pathogenic process in all ACS
patients, and on the therapeutic standards in our institu-
tion (non-ST elevation patients also undergo urgent in-
vasive therapy).
The results of the present study suggest that dynamic
changes in Lp-PLA2 levels during ACS are characterized
by a rapid decrease in initially elevated levels. The altera-
tions in the levels of Lp-PLA2 significantly correlated
with LDL levels. On the other hand, no association was
found between the levels of Lp-PLA2 and CRP or Tnl.
Our data provide indirect support for the hypothesisthat Lp-PLA2 plays an active role in the pathogenesis of
ACS.
Competing interests
Authors declare that they do not have any competing interests.
Authors’ contribution
PO: conception and design of the trial, manuscript drafting; DV: laboratory
and clinical data analysis and interpretation, manuscript drafting; AK: clinical
data analysis and interpretation, critical revision of the manuscript. MJ:
laboratory data analysis and interpretation, critical revision of the manuscript.
HP: manuscript drafting. MP: conception and design of the trial, critical
revision of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This study was supported by a grant from the Czech Ministry of Health, Nr.
NT12153.
Author details
1Department of Cardiology, Heart Center, Na Homolce Hospital,
Roentgenova 2, 150 30 Prague, Czech Republic. 2Department of Clinical
Biochemistry, Hematology, and Immunology, Na Homolce Hospital, Prague,
Czech Republic.
Received: 22 April 2012 Accepted: 6 November 2012
Published: 10 November 2012
References
1. Colley KJ, Wolfert RL, Cobble ME: Lipoprotein associated phospholipase A
(2): role in atherosclerosis and utility as a biomarker for cardiovascular
risk. EPMA J 2011, 2(1):27–38.
2. Epps KC, Wilensky RL: Lp-PLA- a novel risk factor for high-risk coronary
and carotid artery disease. J Intern Med 2011, 269(1):94–106.
3. Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2
in atherosclerosis: biology, epidemiology, and possible therapeutic
target. Arterioscler Thromb Vasc Biol 2005, 25(5):923–931.
4. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R:
Lipoprotein-associated phospholipase A2 protein expression in the
natural progression of human coronary atherosclerosis. Arterioscler
Thromb Vasc Biol 2006, 26(11):2523–2529.
5. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M,
Oldgren J, Rossi GP, Maiolino G, Cesari M, et al: Collaborative meta-
analysis of individual participant data from observational studies of
Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil
2007, 14(1):3–11.
6. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S,
Ballantyne C, Cannon CP, Criqui M, Cushman M, et al: Lipoprotein-
associated phospholipase A(2) and risk of coronary disease, stroke, and
mortality: collaborative analysis of 32 prospective studies. Lancet 2010,
375(9725):1536–1544.
7. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J,
Macphee CH, Suckling KE, Krishna M, Wilkinson FE, et al: Lipoprotein-
associated phospholipase A2 as an independent predictor of coronary
heart disease. West of scotland coronary prevention study group. N Engl
J Med 2000, 343(16):1148–1155.
8. O’Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon
CP, Braunwald E: Lipoprotein-associated phospholipase A2 and its
association with cardiovascular outcomes in patients with acute
coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or
atorVastatin Evaluation and Infection Therapy-Thrombolysis In
Myocardial Infarction) trial. Circulation 2006, 113(14):1745–1752.
9. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL:
Lipoprotein-associated phospholipase A2 and prognosis after myocardial
infarction in the community. Arterioscler Thromb Vasc Biol 2006,
26(11):2517–2522.
10. Oldgren J, James SK, Siegbahn A, Wallentin L: Lipoprotein-associated
phospholipase A2 does not predict mortality or new ischaemic events in
acute coronary syndrome patients. Eur Heart J 2007, 28(6):699–704.
Ostadal et al. Lipids in Health and Disease 2012, 11:153 Page 5 of 5
http://www.lipidworld.com/content/11/1/15311. Vondrakova D, Ostadal P, Kruger A: Immediate effect of intensive
atorvastatin therapy on lipid parameters in patients with acute coronary
syndrome. Lipids Health Dis 2010, 9:71.
12. Ostadal P, Alan D, Vejvoda J, Cepova J, Kukacka J, Blasko P, Martinkovicova L,
Vojacek J: Immediate effect of fluvastatin on lipid levels in acute coronary
syndrome. Mol Cell Biochem 2007, 306(1–2):19–23.
doi:10.1186/1476-511X-11-153
Cite this article as: Ostadal et al.: Alteration in lipoprotein-associated
phospholipase A2 levels during acute coronary syndrome and its
relationship to standard biomarkers. Lipids in Health and Disease 2012
11:153.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
